Investment Rating - The industry investment rating is "Buy" [1] Core Insights - The report highlights the rapid growth of synthetic biology, with a significant increase in the number of synthetic biology companies in Beijing's Changping District, which has surged nearly 70% compared to the same period last year, reaching a total of 146 companies [9] - The establishment of the world's largest pilot transformation platform by Huaxi Biological in Tianjin, which has a total investment of several billion yuan and spans 40,000 square meters, is a key development in the industry [10] - The National Development and Reform Commission has issued the "14th Five-Year Plan for the Development of the Bioeconomy," indicating a trillion-yuan market potential in the bioeconomy sector [4] Market Dynamics - The Huaxi Synthetic Biology Index decreased by 0.49% to 1271.82 during the week of February 24-27, 2026, underperforming compared to the Shanghai Composite Index, which rose by 1.98% [5] - The report notes that the synthetic biology sector is experiencing a wave of technological advancements and increased investment, with nearly 100 companies completing new financing rounds since 2025 [33] Company Developments - Huaxi Biological's pilot platform has already undertaken over 30 biological manufacturing projects, facilitating the transition from laboratory-scale to commercial-scale production [10] - The report mentions that Lif Biological's PEF (polyethylene furanoate) has received approval for food contact use, marking a significant step for bio-based materials in the food packaging sector [24] - Watson Biological has announced a 450 million yuan investment to establish a fund focused on synthetic biology, with a target size of 1 billion yuan [25] Industry Financing - The report indicates that financing in the synthetic biology sector is accelerating, with companies like Rhein Biological and EcoviaBio completing multiple rounds of financing to expand their production capabilities [33][34] - Rhein Biological is focusing on two main development directions: enhancing its core business and providing industrialization services for external synthetic biology products [34]